STA
REGN icon

Summit Trail Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Summit Trail Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.33M Buy
3,017
+483
+19% +$370K 0.03% 431
2025
Q4 		$1.96M Sell
2,534
-533
-17% -$362K 0.03% 424
2025
Q3 		$1.72M Buy
3,067
+796
+35% +$450K 0.02% 524
2025
Q2 		$1.19M Buy
2,271
+616
+37% +$344K 0.02% 410
2025
Q1 		$1.05M Buy
1,655
+259
+19% +$178K 0.03% 150
2024
Q4 		$994K Buy
1,396
+6
+0.4% +$5.04K 0.04% 140
2024
Q3 		$1.46M Buy
1,390
+133
+11% +$148K 0.04% 206
2024
Q2 		$1.32M Buy
1,257
+108
+9% +$105K 0.03% 193
2024
Q1 		$1.11M Buy
1,149
+111
+11% +$106K 0.03% 205
2023
Q4 		$912K Sell
1,038
-64
-6% -$52.7K 0.03% 193
2023
Q3 		$907K Buy
1,102
+38
+4% +$29.9K 0.03% 181
2023
Q2 		$765K Buy
1,064
+244
+30% +$188K 0.03% 196
2023
Q1 		$674K Buy
820
+157
+24% +$118K 0.03% 180
2022
Q4 		$478K Buy
663
+22
+3% +$16.2K 0.02% 193
2022
Q3 		$442K Sell
641
-247
-28% -$155K 0.02% 198
2022
Q2 		$525K Buy
888
+32
+4% +$20.8K 0.03% 175
2022
Q1 		$598K Buy
+856
New +$542K 0.05% 144
2018
Q3 		– Sell
-329
Closed -$114K – 414
2018
Q2 		$114K Buy
+329
New +$103K 0.04% 195
2018
Q1 		– Sell
-721
Closed -$275K – 1372
2017
Q4 		$275K Buy
+721
New +$292K 0.03% 342

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Summit Trail Advisors's REGN Position: Q1 2026 in Review

Summit Trail Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 19% in Q1 2026, buying an estimated $370K and bringing the position to 3,017 shares worth $2.33M. The position accounts for 0.03% of the portfolio, ranked #431.

Summit Trail Advisors first reported a position in REGN in Q4 2017 and has held it in 19 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Summit Trail Advisors held 3,017 shares of Regeneron Pharmaceuticals worth $2.33M as of Q1 2026.
  • Summit Trail Advisors bought 483 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $370K.
  • Regeneron Pharmaceuticals made up 0.03% of Summit Trail Advisors's portfolio in Q1 2026, its #431 holding.
  • Summit Trail Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 19 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.